According to Cuban television reports on Cuba’s vaccine progress, executives from the Center for Genetic Engineering and Biotechnology (CIGB) and the Finlay Vaccine Institute (IVF) reported that in all the vaccination centers to date, over 1,346,000 volunteers have been vaccinated with at least one dose of the Abdala or Soberana. Meanwhile, 770,390 have received the second dose and 148,738 have received the third dose.
The completion of Phase III trials in the two most advanced vaccine candidates on the Island has allowed intervention studies to be carried out to protect the most vulnerable sectors of the population.
By the end of June, Havana, with a population of close to two million inhabitants, everybody should be vaccinated, with 50% having received two doses. The total number of volunteers to be vaccinated in the capital will amount to 854,860.
As of May 31, at least one dose of Abdala had been applied to over 700,000 volunteers in Havana.
Medical personnel, the elderly, and other segments of the population have been involved in these studies.
A total of 1,856 health workers have been certified at each of the vaccination sites.
Dr. Dagmar García, the representative of the Finlay Institute, said that a clinical study of 350 patients between 3 and 18 years of age is progressing. Studies are also being designed for vulnerable groups (diabetics, hypertensive patients and pregnant women). This will be announced in the near future.
Related News:
David Urra is the chief marketing analyst at International Consulting & Representation Services/Cuba (IcarusCuba). He has produced market studies for a wide range of Latin American, European and U.S. clients exploring market entry possibilities in Cuba’s IT, tourism, ranching, pharmaceutical and manufacturing sectors.
